$PCVX
Vaxcyte, Inc.

2021 Q4 Form 10-Q Financial Statement

#000156459021056178 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.92M $10.83M $4.900M
YoY Change 148.91% 120.98%
% of Gross Profit
Research & Development $17.92M $20.43M $16.41M
YoY Change 22.25% 24.49% 70.4%
% of Gross Profit
Depreciation & Amortization $459.0K $510.0K $330.0K
YoY Change 35.0% 54.55%
% of Gross Profit
Operating Expenses $29.85M $26.95M $21.31M
YoY Change 53.43% 26.48% 75.52%
Operating Profit -$26.95M -$21.31M
YoY Change 26.48% 75.52%
Interest Expense $375.0K $37.00K -$500.0K
YoY Change -123.29% -107.4% -5655.56%
% of Operating Profit
Other Income/Expense, Net $908.0K $336.0K $290.0K
YoY Change -170.72% 15.86% -64.76%
Pretax Income -$28.56M -$26.62M -$21.02M
YoY Change 37.72% 26.62%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$28.56M -$26.62M -$21.02M
YoY Change 37.74% 26.63% 85.72%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51
Diluted Earnings Per Share -$540.9K -$510.0K -$413.0K
COMMON SHARES
Basic Shares Outstanding 52.79M 52.19M
Diluted Shares Outstanding 52.19M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $246.0M $278.6M $397.0M
YoY Change -36.31% -29.83%
Cash & Equivalents $68.99M $112.9M $397.0M
Short-Term Investments $177.0M $166.5M
Other Short-Term Assets $10.38M $24.37M $3.800M
YoY Change 270.64% 541.39%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $256.3M $302.9M $400.8M
YoY Change -34.1% -24.42%
LONG-TERM ASSETS
Property, Plant & Equipment $7.954M $6.626M $2.539M
YoY Change 143.09% 160.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $27.12M $39.74M
YoY Change
Other Assets $4.089M $3.580M $442.0K
YoY Change 643.45% 709.95%
Total Long-Term Assets $67.99M $51.12M $2.981M
YoY Change 1678.89% 1614.83%
TOTAL ASSETS
Total Short-Term Assets $256.3M $302.9M $400.8M
Total Long-Term Assets $67.99M $51.12M $2.981M
Total Assets $324.3M $354.1M $403.8M
YoY Change -17.43% -12.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.758M $25.71M $10.69M
YoY Change -77.31% 140.65%
Accrued Expenses $8.787M $12.03M $2.870M
YoY Change 133.32% 319.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.72M $47.46M $39.61M
YoY Change -38.72% 19.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $96.00K $98.00K $128.0K
YoY Change -14.29% -23.44%
Total Long-Term Liabilities $96.00K $98.00K $128.0K
YoY Change -14.29% -23.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.72M $47.46M $39.61M
Total Long-Term Liabilities $96.00K $98.00K $128.0K
Total Liabilities $40.32M $48.11M $39.74M
YoY Change -14.18% 21.06%
SHAREHOLDERS EQUITY
Retained Earnings -$298.6M -$270.1M -$177.8M
YoY Change 50.4% 51.88%
Common Stock $582.9M $576.0M $541.9M
YoY Change 7.07% 6.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $284.0M $306.0M $364.1M
YoY Change
Total Liabilities & Shareholders Equity $324.3M $354.1M $403.8M
YoY Change -17.43% -12.32%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$28.56M -$26.62M -$21.02M
YoY Change 37.74% 26.63% 85.72%
Depreciation, Depletion And Amortization $459.0K $510.0K $330.0K
YoY Change 35.0% 54.55%
Cash From Operating Activities -$51.09M -$28.42M -$13.05M
YoY Change 374.4% 117.74%
INVESTING ACTIVITIES
Capital Expenditures -$1.382M -$1.719M -$30.00K
YoY Change 89.32% 5630.0%
Acquisitions
YoY Change
Other Investing Activities $1.464M -$16.75M $50.00K
YoY Change -33600.0%
Cash From Investing Activities $82.00K -$18.47M $20.00K
YoY Change -111.23% -92445.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.754M 7.599M 40.00K
YoY Change 1491.64% 18897.5%
NET CHANGE
Cash From Operating Activities -51.09M -28.42M -13.05M
Cash From Investing Activities 82.00K -18.47M 20.00K
Cash From Financing Activities 8.754M 7.599M 40.00K
Net Change In Cash -42.26M -39.28M -12.99M
YoY Change 285.91% 202.42%
FREE CASH FLOW
Cash From Operating Activities -$51.09M -$28.42M -$13.05M
Capital Expenditures -$1.382M -$1.719M -$30.00K
Free Cash Flow -$49.71M -$26.70M -$13.02M
YoY Change 395.13% 105.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
837-0111
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
24373000
CY2020Q4 pcvx Accrued Manufacturing Expenses
AccruedManufacturingExpenses
13012000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3M25D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.812
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3822000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3580000
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
871000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
386200000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
166532000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2804000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
302949000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
29785000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
51119000
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52785136
CY2020Q4 us-gaap Assets Current
AssetsCurrent
389004000
dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3272000
CY2021Q3 us-gaap Long Term Investments
LongTermInvestments
39735000
CY2020Q4 us-gaap Assets
Assets
392826000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6626000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
307000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PCVX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.930
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.810
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.818
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.935
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52587855
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52587855
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51071593
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51071593
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
56000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
54000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
575990000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
544353000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-270078000
CY2021Q3 pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
0
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4898000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
90000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
33000
CY2021Q3 pcvx Grant Income
GrantIncome
299000
CY2021Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
1000
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-54000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
336000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-26615000
us-gaap Net Income Loss
NetIncomeLoss
-68480000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.39
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.06
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52187303
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-26615000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-4000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26619000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
345843000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
487000
CY2021Q1 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
9000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1865000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-21220000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
677000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-198564000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3766000
CY2020Q3 pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
143000
pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
2359000
pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
458000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20428000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
553000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16410000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55337000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
305956000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
345843000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
284000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
354068000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
392826000
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58903000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6523000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
98000
CY2021Q3 us-gaap Liabilities
Liabilities
48112000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
us-gaap Net Income Loss
NetIncomeLoss
-71514000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18487000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11225000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
26951000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21308000
us-gaap Operating Expenses
OperatingExpenses
73824000
us-gaap Operating Expenses
OperatingExpenses
70128000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26951000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21308000
us-gaap Operating Income Loss
OperatingIncomeLoss
-73824000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70128000
us-gaap Interest Expense
InterestExpense
7000
us-gaap Interest Expense
InterestExpense
7000
us-gaap Investment Income Interest
InvestmentIncomeInterest
245000
us-gaap Investment Income Interest
InvestmentIncomeInterest
212000
CY2020Q3 pcvx Grant Income
GrantIncome
787000
pcvx Grant Income
GrantIncome
677000
pcvx Grant Income
GrantIncome
2152000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
2000
us-gaap Net Income Loss
NetIncomeLoss
-71514000
us-gaap Net Income Loss
NetIncomeLoss
-68480000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-530000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-12000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1393000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-709000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
290000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2310000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1648000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21018000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50895358
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51627249
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22354212
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21018000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21018000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71526000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68480000
CY2020Q1 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
128000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
372000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
297000
CY2020Q2 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
12000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12120000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-106373000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
466000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
326937000
CY2021Q2 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
2000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
490000
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
10001000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2769000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
39000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23679000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
317025000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
491000
CY2021Q3 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
2000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2937000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-26615000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
305956000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
49000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-27142000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-132966000
CY2020Q2 pcvx Temporary Equity Conversion Of Preferred Stock Value
TemporaryEquityConversionOfPreferredStockValue
270190000
CY2020Q2 pcvx Adjustments To Additional Paid In Capital Warrant Liability Write Off
AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff
629000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
264079000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1289000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20320000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
383210000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
108000
CY2020Q3 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
9000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
72000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1838000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21018000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
364075000
us-gaap Profit Loss
ProfitLoss
-71514000
us-gaap Profit Loss
ProfitLoss
-68480000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1341000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1073000
us-gaap Share Based Compensation
ShareBasedCompensation
7571000
us-gaap Share Based Compensation
ShareBasedCompensation
3499000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
179000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
910000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-910000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-32000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-32000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
267000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
16306000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1040000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3030000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-33000
pcvx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
75000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5601000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7330000
pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
1791000
pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
1076000
pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
-5979000
pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
18763000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8448000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1416000
pcvx Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
-8000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-70300000
CY2020Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
264000000.0
CY2020Q2 pcvx Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
20100000
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3400000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35860000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5173000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
433000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
50000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
295279000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
58000000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
30062000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-212390000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-383000
pcvx Payments Of Capital Lease Obligations
PaymentsOfCapitalLeaseObligations
61000
pcvx Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts
ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts
267375000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3368000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
109879000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1444000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
454000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7108000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
36000
pcvx Proceeds From Issuance Of Common Stock Under The Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan
490000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9042000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
374315000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-273285000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
338072000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
386200000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58976000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112915000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
397048000
us-gaap Interest Paid Net
InterestPaidNet
7000
us-gaap Interest Paid Net
InterestPaidNet
7000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
271000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
149000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
270190000
pcvx Issuance Costs For Initial Public Offering Included In Accounts Payable And Accrued Expenses
IssuanceCostsForInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpenses
17000
us-gaap Stock Issued1
StockIssued1
10000000
pcvx Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
154000
pcvx Proceeds From Issuance Of Common Stock Not Yet Received
ProceedsFromIssuanceOfCommonStockNotYetReceived
5011000
CY2020Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-1.6870
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the determination of our incremental borrowing rate, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. </p>
pcvx Number Of Finance Lease
NumberOfFinanceLease
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally-insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the condensed balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to supplier concentration risk from our suppliers. We source our critical raw materials from a sole source supplier, Sutro Biopharma, Inc. (“Sutro Biopharma”). We also use one contract manufacturing organization (“CMO”), Lonza Ltd. (“Lonza”), to handle most of our manufacturing activities. If we were to experience disruptions in raw materials supplied by Sutro Biopharma, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.  </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the “Risk Factors” section of this Quarterly Report on Form 10-Q.</p>
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
900000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
900000
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
166532000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
39735000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
206267000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12045000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7369000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5419000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4097000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6626000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3272000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
CY2021Q3 pcvx Accrued Preclinical Studies Current
AccruedPreclinicalStudiesCurrent
6335000
CY2020Q4 pcvx Accrued Preclinical Studies Current
AccruedPreclinicalStudiesCurrent
2844000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
643000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
490000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5049000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
432000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12027000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3766000
pcvx Number Of Operating Lease
NumberOfOperatingLease
2
us-gaap Operating Lease Payments
OperatingLeasePayments
920000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
307000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
613000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
553000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1166000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2021Q3 pcvx Lessee Operating Lease Liability Payments Net Of Lease Incentives Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear
253000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
487000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
379000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
388000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
398000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1399000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
233000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1166000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
742000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
190000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
932000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52587855
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52587855
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51071593
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51071593
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
62382
CY2020Q2 pcvx Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
46869
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021Q3 pcvx Early Exercised Stock Options
EarlyExercisedStockOptions
8337
CY2020Q4 pcvx Early Exercised Stock Options
EarlyExercisedStockOptions
15056
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
62382
CY2021Q3 pcvx Number Of Options Exercised Excludes Options Exercised From Npln
NumberOfOptionsExercisedExcludesOptionsExercisedFromNPLN
125583
CY2020Q3 pcvx Number Of Options Exercised Excludes Options Exercised From Npln
NumberOfOptionsExercisedExcludesOptionsExercisedFromNPLN
67792
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.91
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.60
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.00
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
29.83
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2500000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2500000
pcvx Number Of Options Exercised Excludes Options Exercised From Npln
NumberOfOptionsExercisedExcludesOptionsExercisedFromNPLN
578194
pcvx Number Of Options Exercised Excludes Options Exercised From Npln
NumberOfOptionsExercisedExcludesOptionsExercisedFromNPLN
263626
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5100000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.003
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21018000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-71514000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26615000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.06
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50895358
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51627249
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22354212
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.39
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68480000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52187303
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-21-056178-index-headers.html Edgar Link pending
0001564590-21-056178-index.html Edgar Link pending
0001564590-21-056178.txt Edgar Link pending
0001564590-21-056178-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gxbjvoc5fasg000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pcvx-10q_20210930.htm Edgar Link pending
pcvx-10q_20210930_htm.xml Edgar Link completed
pcvx-20210930.xsd Edgar Link pending
pcvx-20210930_cal.xml Edgar Link unprocessable
pcvx-20210930_def.xml Edgar Link unprocessable
pcvx-20210930_lab.xml Edgar Link unprocessable
pcvx-20210930_pre.xml Edgar Link unprocessable
pcvx-ex101_97.htm Edgar Link pending
pcvx-ex311_8.htm Edgar Link pending
pcvx-ex312_7.htm Edgar Link pending
pcvx-ex321_9.htm Edgar Link pending
pcvx-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending